Hologic Gets FDA Clearance For Cancer-Cell Diagnostic System
By Ben Glickman
Hologic said Thursday it had received clearance from regulators for its cancer-cell detecting digital diagnostic system.
The Marlborough, Mass.-based medical technology company said it expects its Genius Digital Diagnostics System to become available in early 2024.
According to Hologic, its system uses artificial intelligence and imaging technology to help locate pre-cancerous lesions and cervical cancer cells.
The company said it was the first FDA-cleared digital cytology system.
The system can read glass slides from pap test used to screen for cervical cancer. The Genius system identifies cells that experts should review.
Hologic's system is already available in Europe, Australia and New Zealand.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
February 01, 2024 18:32 ET (23:32 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations